REAURO001

REAURO001 is a small molecule drug candidate being developed by Reach Pharmaceuticals for the treatment of overactive bladder (OAB). It is a 'Reach-Enhanced' version of a muscarinic antagonist, designed using the company's proprietary technology to optimize the pharmacokinetic profile and reduce systemic side effects. By improving the delivery of the active ingredient, REAURO001 aims to mitigate common anticholinergic effects such as xerostomia (dry mouth) and constipation, which often lead to poor patient compliance with existing OAB therapies. The drug is currently in early-stage clinical development, with the goal of providing a more tolerable alternative to standard-of-care muscarinic antagonists.